Compass Therapeutics, Inc.
CMPX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | -0.27 | -0.43 | -0.07 |
| FCF Yield | 0.00% | -3.29% | -5.04% | -4.62% |
| EV / EBITDA | -30.70 | -16.45 | -12.95 | -9.95 |
| Quality | ||||
| ROIC | 0.00% | -20.43% | -15.40% | -12.57% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | 0.60 | 0.79 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 947,168.24% | 947,168.24% |
| Free Cash Flow Growth | 100.00% | 10.54% | -44.36% | 17.42% |
| Safety | ||||
| Net Debt / EBITDA | 3.24 | 0.61 | 1.97 | 2.27 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -636.38 | 0.00 | 0.00 |